Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...
Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...
InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...
In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and ...
Multiple treatment strategies have been demonstrated to be effective (Table 3). Although all of these agents have different modes of action, they universally affect the immune system in some way. As ...
A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results